Evidence map›Paper›PMID 31671023›Full record

ArticleActa oncologica (Stockholm, Sweden)2020

17β-Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence: a Danish population-based study.

Lindsay J Collin, Sinna P Ulrichsen, Thomas P Ahern, Michael Goodman, Lauren E McCullough, Lance A Waller, Kristina Bang Christensen, Per Damkier, Stephen Hamilton-Dutoit, Kristina L Lauridsen and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. The Obesity-Related Metabolic Gene HSD17B8 Protects Against Breast Cancer: High RNA/Protein Expression Means a Better Prognosis.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lindsay J CollinDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-0170-2592
Sinna P UlrichsenDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Thomas P AhernDepartment of Surgery, The Robert Larner, M.D. College of Medicine, The University of Vermont, Burlington, VT, USA.
Michael GoodmanDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Lauren E McCulloughDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Lance A WallerDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-5002-8886
Kristina Bang ChristensenInstitute of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Per DamkierDepartment of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.ORCID http://orcid.org/0000-0003-0591-7187
Stephen Hamilton-DutoitInstitute of Pathology, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-2158-3885
Kristina L LauridsenInstitute of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Rami YacoubDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Peer M ChristiansenBreast Unit, Aarhus University Hospital/Randers Regional Hospital, Aarhus, Denmark.
Bent EjlertsenDanish Breast Cancer Group, Copenhagen, Denmark.
Henrik Toft SørensenDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-4299-7040
Deirdre P Cronin-FentonDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0001-9738-2284
Timothy L LashDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5240-5195

Funding

Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI LANSING, AMY HUGHES · 2013 to 2022
$21.3M
New and integrated perspectives on modification of tamoxifen effectivenessR01CA166825 · NCI · EMORY UNIVERSITY · PI LASH, TIMOTHY L. · 2013 to 2017
$2.8M
Modification of tamoxifen effectiveness by gene polymorphisms and other drugsR01CA118708 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LASH, TIMOTHY L. · 2006 to 2009
$963k
Biologic and Patient Variation Affecting Breast Cancer Treatment EfficacyF31CA239566 · NCI · EMORY UNIVERSITY · PI COLLIN, LINDSAY JANE · 2019 to 2020
$53k
NCI NIH HHS F31 CA239566NCI NIH HHS R01 CA118708NCI NIH HHS R01 CA166825NIGMS NIH HHS P20 GM103644
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsCase-Control StudiesDenmarkEstradiol DehydrogenasesFemaleFollow-Up StudiesHumansIncidenceMiddle AgedNeoplasm Recurrence, LocalPrognosisTamoxifenAntineoplastic Agents, HormonalBiomarkers, TumorEstradiol DehydrogenasesHSD17B1 protein, humanHSD17B2 protein, humanTamoxifen

Identifiers

PMID31671023
PMCPMC7033004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.